Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Shares of Arvinas ARVN plummeted 52.7% on Tuesday after the company and partner, Pfizer PFE, announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.